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Abstract
Background: Neonatal jaundice is a common major problem; on the other hand, it is suggested that there is a correlation between
plasma magnesium concentrations and hyperbilirubinemia during the neonatal period.
Objectives: The study aims to validate a previously reported risk index for predicting the magnesium level of plasma for moderate
to severe hyperbilirubinemia in infant neonates.
Methods: A cross-sectional correlation study was performed on 93 term newborns with indirect hyperbilirubinemia admitted in
neonatology unit of a children hospital and plasma magnesium level of moderate to severe Neonatal hyperbilirubinemia were
determined, and statistical analysis was performed.
Results: Authors did not find any statistically meaningful positive or negative correlation between plasma Mg level and bilirubin
in patients studied; however, comparison of Mg level in two groups of severe and moderate hyperbilirubinemia showed decreased
dispersion of medium Mg level in the severe group.
Conclusions: Serum magnesium concentration is not useful in anticipation of which newborn infant will develop hyperbilirubine-
mia.
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1. Background
Hyperbilirubinemia, a common problem in neonate
infants (1-3), is seen in about 80% of preterm and 60% of
term newborns during the first days of life (4, 5). Bilirubin
is considered as a neurotoxic agent (3, 6), injures neural cell
membranes and damages membrane enzymes and recep-
tors (7-9), and results in neurologic deficit in infants (10).
Furthermore, structures such as N-methyl D-aspartate
(NMDA) receptor, located in the synaptic surface of the
cell membrane structure, is subjected to the bilirubin in-
jury; therefore, neurologic development and learning and
memory disorders in childhood is due.
Many reports have suggested magnesium (Mg) as a
neuroprotective factor, which protects central nervous sys-
tem against hypoxia, and comprises supportive effects of
neurons (11-14). Physiologic effects of Mg are opposite of
bilirubin neurotoxic effects (15, 16). Mg is one of the most
important NMDA regulatory antagonists in the neural sur-
face, which reverses the damaging cell membrane mecha-
nisms by receptor blocking, and finally, leads to neural sys-
tem protection.
Hence, it seems that plasma Mg level manifests the
metabolic and physiologic states of a neonate with hyper-
bilirubinemia.
2. Objectives
Although Mg regulatory and protective effects on the
NMDA receptor is completely known, Mg and hyperbiliru-
binemia relation is not studied well. This study is designed
to assess any relation between Mg plasma level and moder-
ate to severe hyperbilirubinemia.
3. Methods
This was a correlation study carried out on 93 term
neonates admitted to the Aliasghar Children Hospital
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Neonatal Ward in Tehran, IR Iran, during Apr. to Sep.
2012. The inclusion criteria was moderate to severe hy-
perbilirubinemia required treatment in term neonates,
according to Bhutani nomogram, nearly 16 to 20 mg/dL
for patients with moderate hyperbilirubinemia, and more
than 20 mg/dL for severely affected neonates. The exclu-
sion criteria included anemia with hemoglobin less than
8.7 g/dL or hemolysis evidence, G6PD enzyme deficiency,
red blood cell membrane disorders, MgSO4 use in the pre-
natal period, and major congenital anomalies.
Every infant has undergone two blood sampling.
Serum Mg level was analyzed by the Becton Dickinson
Vacutainer system, France, measured by the Ion-selective
electrode (ISE) method. Serum bilirubin was assayed with
colorimetric method by the use of Diazotized Sulfanilic
acid reaction; Roche diagnostic kit, USA.
Hyperbilirubinemia was classified into two groups of
severe (total bilirubin more than 20 mg/dL) and moder-
ate (total bilirubin ≤ 20 mg/dL). Mg level greater than 2.3
mg/dL was defined as hypermagnesemia, and Mg level less
than 1.5 mg/dL was assumed as hypomagnesemia.
Data analysis was performed by the use of SPSS 17. Var-
ious parameters co-efficient were assessed by the Pearson
test. Group comparison was carried out by Ki square and
independent t-test, according to the qualitative or quanti-
tative nature of P value; and P values less than 0.05 were
assumed statistically meaningful.
4. Results
Among 93 jaundiced term neonates with moderate to
severe hyperbilirubinemia, 39% were female; and 61% were
male. Moderate hyperbilirubinemia, in a study popula-
tion, was 88.2% (82 patients), and frequency of severe hy-
perbilirubinemia was 11.8% (11 of 93 patients). Among the
infants studied, medium serum bilirubin level was 18.29
± 1.8 mg/dL (with range of 12.3 to 24 mg/dL), and medium
plasma Mg level was 1.9 ± 0.3 mg/dL (range of 1.3 to 2.7
mg/dL).
In neonates with moderate hyperbilirubinemia,
medium serum bilirubin was 17.7 ± 1.27 mg/dL, and
medium infant age was 6.8 ± 3.9 days, with medium birth
weight of 3018 ± 413 grams; medium plasma Mg level was
1.9 ± 0.3 mg/dL.
In neonates with severe hyperbilirubinemia, medium
serum bilirubin was 22.11± 1.19, medium infant age was 6.6
± 3.3 days, and medium infant weight at birth was 3091 ±
639 grams; medium severe Mg level was 1.9 ± 0.2 mg/dL.
According to this study the relation of hyperbilirubine-
mia with infant sex (P = 0.368), neonate age (P = 0.89), and
birth weight (P = 0.63) was not statistically meaningful.
Statistical analysis didn’t reveal any meaningful corre-
lation between hyperbilirubinemia and high plasma Mg
level (P = 0.368), or low plasma Mg level (P = 0.305).
Comparison of Mg level in two groups of severe and
moderate hyperbilirubinemia showed decreased disper-
sion of medium Mg level in the severe group, however, this
finding is not statistically meaningful (P > 0.05).
5. Discussion
Magnesium, the second frequent intracellular cation,
is essential for fetal growth, and Mg deficiency in preg-
nancy is associated with eclampsia or pre-eclampsia, pre-
mature labor, prolonged duration of maternal hospitaliza-
tion, and infant low birth weight (15).
Relevant past studies have demonstrated neuropro-
tective effects of ionized Mg (11-14). On the other hand,
neurotoxic property of indirect bilirubin (10) proposed
the hypothesis about the relationship between plasma
Mg and bilirubin level in hyperbilirubinemic newborn in-
fants. Sapkota found a significant difference in the Mg
concentrations before and after phototherapy correspond-
ingly bilirubin levels before and after phototherapy and
concluded that phototherapy could decrease serum Mg
level as much as Bilirubin. He concluded that there was
a positive relation between serum Mg and bilirubin levels
and propounded that rising of Mg in hyperbilirubinemia
might be a compensatory mechanism against toxic effects
of bilirubin (16).
The recent study revealed the Mg level in infants with
severe hyperbilirubinemia a little higher than the moder-
ate hyperbilirubinemic group (1.90 ± 0.3 mg/dL and 1.91
± 0.2 mg/dL, respectively), which was not statistically sig-
nificant. Past studies propounded contradictory opinions
on this subject. Dennery et al., referred to a positive corre-
lation of serum Mg level and hyperbilirubinemia severity;
and thought that increased cell damage is the cause of hy-
permagnesemia. There are some reports representing that
bilirubin not only harms neurons, but also affects other
types of cells by their toxic effects (17).
Ilves et al. (18) and Engle and Elin (19) reported in-
creased serum Mg level in asphyxia. Furthermore, Olofs-
son et al. (20), and Sarici et al. (21), thought that hyper-
magnesemia leads to acidosis and hypoxemia, which in
turn, may cause irreparable effects in neural cells. Some re-
searchers suggested ionized Mg as a NMDA receptor block-
ing ion. Hyperactivity of NMDA receptors on the neu-
ron membrane, during the intrauterine period, leads to
ischemic encephalopathy; bilirubin affects NMDA in this
way, and magnesium ion acts as a neuroprotective sub-
stance by blocking the NMDA receptors in neural cells.
In the animal models studied, increased bilirubin level
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changed the membrane NMDA receptor activity and led to
neuronal injuries (7-9, 22).
Sakamoto et al. (23), demonstrated that there isn’t any
association between plasma and cerebrospinal fluid Mg
level in patients with cerebral injuries; this may be due to
the blood brain barrier presence. This finding is compat-
ible with our study results. On the other hand, Sarici et
al. (24), explained that elevated plasma Mg level in neona-
tal diseases such as respiratory distress syndrome or hy-
perbilirubinemia is due to acidosis and hypoxia resulting
from generalized cellular damage including erythrocytes
and neurons and extracellular movement of principally in-
tracellular Mg ion (24). In a study performed by Yasser et
al., the mean levels of plasma Mg were significantly higher
in hemolytic unconjugated hyperbilirubinemic neonates
compared to controls and non-hemolytic cases, which was
thought to be due to the extracellular movement of Mg
from erythrocytes (25).
Pintov et al., did not find any significant correlation
between the highest serum bilirubin concentrations and
cord serum concentrations of zinc, magnesium, and cop-
per. They concluded that cord serum concentrations of
magnesium, zinc, and copper were not predictive that
which newborns would develop hyperbilirubinemia; their
report is coordinated with the recent study (26).
There are some other paradoxical reports in the liter-
ature review, which may be due to prematurity. Perveen
et al., showed that copper and magnesium remained in
cord blood plasma at much less concentrations compared
with the mother throughout the last trimester suggesting
that the gestational age may have a major role in plasma
Mg level in neonates and resulting adverse effects of hy-
perbilirubinemia (27). Cultural and socioeconomic differ-
ences due to genetic, geographical, and nutritional diver-
sity may be involved in the paradoxical results. Baig et al.,
studied on zinc, copper, magnesium, calcium, and phos-
phorous levels in maternal and cord blood and demon-
strated that Mg levels were higher in Pakistani women’s
blood in comparison of cord blood (28).
5.1. Conclusions
Serum concentrations of magnesium were not prof-
itable in the prediction of which neonates would de-
velop moderate to severe indirect hyperbilirubinemia. Al-
though, we did not find any statistically meaningful posi-
tive or negative correlations between plasma Mg level and
bilirubin in patients studied; comparison of Mg level in
two groups of severe and moderate hyperbilirubinemia
showed decreased dispersion of medium Mg level in severe
group.
It is recommended that plasma Mg levels need to be
studied in jaundiced neonates in comparison to patients
without considerable jaundice; and also, plasma Mg levels
in mothers of neonates with hyperbilirubinemia. Further-
more, comparison of NMDA receptor numbers in healthy
and jaundiced neonates or animal models may be a subject
of future studies.
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